Safety, Efficacy, and Pharmacokinetics of Combination SARS-CoV-2 Neutralizing Monoclonal Antibodies BMS-986414 (C135-LS) and BMS-986413 (C144-LS) Administered Subcutaneously in Non-Hospitalized Persons with COVID-19 in a Phase 2 Trial
Related Posts
Liu H, Lee P, Vo A, Paul S, Phan QT, Lin J, Bruno VM, Stamnes MA, Moye-Rowley WS, Filler SG. The HosA histone deacetylase regulates[...]
Shin J, Cooley ME, Hammer MJ, Yang CJ, Hajime U, Maiorino E, Casaburi R, Boueiz ARE, Estepar RSJ, Castaldi PJ; COPDGene Investigators. Clinical History, Spirometry,[...]
Phan JP, Kinninger A, Roy SK, Bhandari M, Budoff MJ. Coronary artery calcium score of zero in individuals with diabetes: association with normal coronary arteries[...]